TrialNature communications2025

Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial.

Adrienne G Waks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.